Search Results for: Schizophrenia

1632 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
BCL9 and CTNNB1 B-cell CLL/lymphoma 9 catenin (cadherin-associated protein), beta 1, 88kDa
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
CTNNB1 and NFKB1 catenin (cadherin-associated protein), beta 1, 88kDa nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Downstream signaling events of B Cell Receptor (BCR)
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • Transcriptional regulation of white adipocyte differentiation
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • TRIF-mediated TLR3/TLR4 signaling
  • Cytosolic sensors of pathogen-associated DNA
  • Senescence-Associated Secretory Phenotype (SASP)
  • Cytokine Signaling in Immune system
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Signaling by Interleukins
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Interleukin-1 processing
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Activation of NF-kappaB in B cells
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Interleukin-1 signaling
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Urea
  • Thalidomide
  • Pranlukast
  • Triflusal
CTNNB1 and PTPRU catenin (cadherin-associated protein), beta 1, 88kDa protein tyrosine phosphatase, receptor type, U
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Signaling by SCF-KIT
  • Urea
CTNNB1 and CTNNA3 catenin (cadherin-associated protein), beta 1, 88kDa catenin (cadherin-associated protein), alpha 3
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
ITIH4 and TP63 inter-alpha-trypsin inhibitor heavy chain family, member 4 tumor protein p63
BAG6 and TP63 BCL2-associated athanogene 6 tumor protein p63
HLA-DQA1 and IKBKG major histocompatibility complex, class II, DQ alpha 1 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRAK1 recruits IKK complex
  • Downstream signaling events of B Cell Receptor (BCR)
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • NOD1/2 Signaling Pathway
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • IRAK1 recruits IKK complex
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Innate Immune System
  • activated TAK1 mediates p38 MAPK activation
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • IKK complex recruitment mediated by RIP1
  • Cytosolic sensors of pathogen-associated DNA
  • Cytokine Signaling in Immune system
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by Interleukins
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Activation of NF-kappaB in B cells
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Adaptive Immune System
APC and SYNE1 adenomatous polyposis coli spectrin repeat containing, nuclear envelope 1
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Programmed Cell Death
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Apoptotic cleavage of cellular proteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Apoptotic execution phase
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Meiotic synapsis
APLP1 and HLA-DQA1 amyloid beta (A4) precursor-like protein 1 major histocompatibility complex, class II, DQ alpha 1
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
CD74 and HLA-DQA1 CD74 molecule, major histocompatibility complex, class II invariant chain major histocompatibility complex, class II, DQ alpha 1
  • MHC class II antigen presentation
  • Adaptive Immune System
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
CDK7 and HLA-DQA1 cyclin-dependent kinase 7 major histocompatibility complex, class II, DQ alpha 1
  • RNA Polymerase II Promoter Escape
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Tat-mediated elongation of the HIV-1 transcript
  • Cyclin E associated events during G1/S transition
  • Formation of transcription-coupled NER (TC-NER) repair complex
  • Dual incision reaction in TC-NER
  • NoRC negatively regulates rRNA expression
  • G1/S Transition
  • Mitotic G1-G1/S phases
  • S Phase
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • Global Genomic NER (GG-NER)
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Cyclin A:Cdk2-associated events at S phase entry
  • Mitotic G2-G2/M phases
  • Transcription of the HIV genome
  • Nucleotide Excision Repair
  • RNA Polymerase II Transcription
  • RNA Polymerase I Transcription Initiation
  • HIV Infection
  • RNA Polymerase I Promoter Clearance
  • Formation of the Early Elongation Complex
  • G2/M Transition
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • HIV Transcription Initiation
  • HIV Life Cycle
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Cyclin A/B1 associated events during G2/M transition
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • Dual incision reaction in GG-NER
  • RNA Polymerase I Transcription
  • mRNA Capping
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase I Transcription Termination
  • G1 Phase
  • Epigenetic regulation of gene expression
  • Negative epigenetic regulation of rRNA expression
  • Cell Cycle, Mitotic
  • Cyclin D associated events in G1
  • Transcription-coupled NER (TC-NER)
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Formation of incision complex in GG-NER
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
  • Phosphonothreonine
  • Flavopiridol
HLA-DQA1 and UNC119 major histocompatibility complex, class II, DQ alpha 1 unc-119 homolog (C. elegans)
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
HLA-DQA1 and LRIF1 major histocompatibility complex, class II, DQ alpha 1 ligand dependent nuclear receptor interacting factor 1
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
HLA-DQA1 and TLE1 major histocompatibility complex, class II, DQ alpha 1 transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • truncations of AMER1 destabilize the destruction complex
  • FBXW7 Mutants and NOTCH1 in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • NOTCH1 Intracellular Domain Regulates Transcription
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by WNT in cancer
HLA-DQA1 and SH3GL2 major histocompatibility complex, class II, DQ alpha 1 SH3-domain GRB2-like 2
  • Generation of second messenger molecules
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • Translocation of ZAP-70 to Immunological synapse
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Interferon gamma signaling
  • TCR signaling
  • MHC class II antigen presentation
  • PD-1 signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
  • Retrograde neurotrophin signalling
  • EGFR downregulation
  • Signalling by NGF
  • Axon guidance
  • Golgi Associated Vesicle Biogenesis
  • L1CAM interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • Clathrin derived vesicle budding
  • Lysosome Vesicle Biogenesis
  • Signaling by EGFR
  • MHC class II antigen presentation
  • Signaling by EGFR in Cancer
  • trans-Golgi Network Vesicle Budding
  • Adaptive Immune System
MDM2 and SMARCA2 MDM2 proto-oncogene, E3 ubiquitin protein ligase SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • Stabilization of p53
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • PIP3 activates AKT signaling
  • Oncogene Induced Senescence
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Signalling by NGF
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Trafficking of AMPA receptors
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • Oxidative Stress Induced Senescence
  • Cell Cycle Checkpoints
  • Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
  • Chromatin modifying enzymes
  • Chromatin organization
  • RMTs methylate histone arginines
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
FLNA and KCNJ2 filamin A, alpha potassium channel, inwardly rectifying subfamily J, member 2
  • Cell junction organization
  • GP1b-IX-V activation signalling
  • Response to elevated platelet cytosolic Ca2+
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • Cell-extracellular matrix interactions
  • GABA B receptor activation
  • Inwardly rectifying K+ channels
  • GABA receptor activation
  • Activation of G protein gated Potassium channels
  • Classical Kir channels
  • Activation of GABAB receptors
  • Potassium Channels
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • G protein gated Potassium channels
  • Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
  • Transmission across Chemical Synapses
KCNJ2 and KCNJ11 potassium channel, inwardly rectifying subfamily J, member 2 potassium channel, inwardly rectifying subfamily J, member 11
  • GABA B receptor activation
  • Inwardly rectifying K+ channels
  • GABA receptor activation
  • Activation of G protein gated Potassium channels
  • Classical Kir channels
  • Activation of GABAB receptors
  • Potassium Channels
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • G protein gated Potassium channels
  • Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
  • Transmission across Chemical Synapses
  • Inwardly rectifying K+ channels
  • Integration of energy metabolism
  • ATP sensitive Potassium channels
  • Regulation of insulin secretion
  • Potassium Channels
  • Glimepiride
  • Ibutilide
  • Verapamil
  • Levosimendan
  • Glyburide
  • Diazoxide
  • Thiamylal
AR and HDAC4 androgen receptor histone deacetylase 4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
AR and TCF4 androgen receptor transcription factor 4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • CDO in myogenesis
  • Myogenesis
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide

Page 2 out of 82 pages